The U.S. Department of Health and Human Services (HHS) recently released a video to health care providers emphasizing the A-rating issued for monoclonal antibody therapies which are intended to keep people with mild to moderate COVID-19 symptoms from requiring hospitalization.
Yet while the attention last week was focused on how many hospital beds are available in Arizona, there was no mention of the difficulty many patients experience getting the highly touted monoclonal antibody therapy in Arizona. This, despite the fact Gov. Doug Ducey provided $60 million to hospitals and other health care providers in September, in part to promote the use of the treatment.
Monoclonal antibodies are made in a laboratory to fight a particular infection—in this case, SARS-CoV-2. The rating from the National Institutes of Health stresses the important role a monoclonal antibody therapy (mAb) can play in reducing the risk that someone infected with COVID-19 will get sicker, said Dr. Rachel Levine, Assistant Secretary for HHS…
___
We at the American Daily Independent News Network are a dedicated team of journalists and subject matter experts solely funded by the financial support of our readers and advertisers.
- We serve millions of readers annually
- We do not accept government funds